Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:CALC NASDAQ:DCOY NASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.38$0.44$0.01▼$3.42$15.50M-1.8340,518 shs100 shsCALCCalciMedica$0.97$0.76$0.46▼$7.20$15.25M0.893.54 million shs403,820 shsDCOYDecoy Therapeutics$7.31$6.32$4.32▼$415.80$3.89M0.59675,806 shs80,073 shsPASGPassage Bio$4.68$5.29$3.29▼$20.00$15.01M1.42149,973 shs44,641 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%-3.80%-5.00%-49.33%-79.01%CALCCalciMedica0.00%+18.32%+12.26%+65.03%-38.90%DCOYDecoy Therapeutics0.00%+32.43%+8.94%+26.03%+730,999,900.00%PASGPassage Bio0.00%-0.43%-22.00%-42.08%-42.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.38$0.44$0.01▼$3.42$15.50M-1.8340,518 shs100 shsCALCCalciMedica$0.97$0.76$0.46▼$7.20$15.25M0.893.54 million shs403,820 shsDCOYDecoy Therapeutics$7.31$6.32$4.32▼$415.80$3.89M0.59675,806 shs80,073 shsPASGPassage Bio$4.68$5.29$3.29▼$20.00$15.01M1.42149,973 shs44,641 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%-3.80%-5.00%-49.33%-79.01%CALCCalciMedica0.00%+18.32%+12.26%+65.03%-38.90%DCOYDecoy Therapeutics0.00%+32.43%+8.94%+26.03%+730,999,900.00%PASGPassage Bio0.00%-0.43%-22.00%-42.08%-42.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/ACALCCalciMedica 2.00Hold$10.00935.84% UpsideDCOYDecoy Therapeutics 2.00Hold$30.00310.40% UpsidePASGPassage Bio 2.11Hold$13.25183.12% UpsideCurrent Analyst Ratings BreakdownLatest DCOY, ANEB, CALC, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026PASGPassage Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/12/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/10/2026PASGPassage Bio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral6/10/2026PASGPassage Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/28/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/7/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/22/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$21.00 ➝ $7.004/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$21.00 ➝ $7.004/21/2026PASGPassage Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $15.004/21/2026PASGPassage Bio TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/ACALCCalciMedicaN/AN/AN/AN/A($0.46) per shareN/ADCOYDecoy TherapeuticsN/AN/AN/AN/A$11.07 per shareN/APASGPassage BioN/AN/AN/AN/A$5.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%9/23/2026 (Estimated)CALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)DCOYDecoy Therapeutics-$12.52M-$106.90N/AN/AN/AN/A-395.42%-193.30%N/APASGPassage Bio-$45.52M-$11.84N/AN/AN/AN/A-150.88%-59.78%7/30/2026 (Estimated)Latest DCOY, ANEB, CALC, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PASGPassage Bio-$2.7640-$2.36+$0.4040-$2.36N/AN/A5/8/2026Q1 2026DCOYDecoy TherapeuticsN/A-$4.18N/A-$4.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/ADCOYDecoy TherapeuticsN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A6.246.24CALCCalciMedicaN/A1.611.61DCOYDecoy TherapeuticsN/A1.841.84PASGPassage BioN/A1.731.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%CALCCalciMedicaN/ADCOYDecoy Therapeutics11.88%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%CALCCalciMedica41.55%DCOYDecoy Therapeutics1.70%PASGPassage Bio4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableCALCCalciMedica3015.80 million9.23 millionNo DataDCOYDecoy Therapeutics20530,000523,000N/APASGPassage Bio1303.21 million3.05 millionNo DataDCOY, ANEB, CALC, and PASG HeadlinesRecent News About These CompaniesPassage Bio (NASDAQ:PASG) Major Shareholder Lynx1 Capital Management Lp Acquires 50,055 Shares of StockJune 30, 2026 | americanbankingnews.comInsider Buying: Passage Bio (NASDAQ:PASG) Major Shareholder Purchases 50,055 SharesJune 30, 2026 | insidertrades.comPassage Bio, Inc. (PASG) M&A Call Prepared Remarks TranscriptJune 25, 2026 | seekingalpha.comPASG stock slumps 16% after-hours — what’s driving the selloff?June 24, 2026 | msn.comPassage Bio and Remix Therapeutics Announce Merger AgreementJune 24, 2026 | markets.businessinsider.comPassage Bio and Remix Therapeutics Announce Merger AgreementJune 24, 2026 | globenewswire.comPassage Bio, Inc. résilie son accord de collaboration de recherche avec Gemma Biotherapeutics, IncJune 3, 2026 | zonebourse.comZPassage Bio Ends Key Collaborations and Office LeaseMay 27, 2026 | tipranks.comPassage Bio Shareholders Approve Directors and Executive PayMay 26, 2026 | tipranks.comPassage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?May 20, 2026 | finance.yahoo.comPassage Bio (PASG) price target decreased by 62.83% to 11.63April 28, 2026 | msn.comTD Cowen downgrades Passage Bio (PASG)April 23, 2026 | msn.comPassage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate UpdatesApril 20, 2026 | globenewswire.comPassage Bio (PASG) Gets a Buy from Chardan CapitalApril 8, 2026 | theglobeandmail.comOppenheimer initiates coverage of Passage Bio (PASG) with outperform recommendationApril 1, 2026 | msn.comPassage Bio (PASG) price target decreased by 22.22% to 31.42March 28, 2026 | msn.comPassage Bio advances frontotemporal dementia trial and reports 2025 resultsMarch 10, 2026 | msn.comPassage Bio Ends Hopewell Lab Lease, Extends Cash RunwayMarch 10, 2026 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Passage Bio (PASG)March 8, 2026 | theglobeandmail.comPassage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business HighlightsMarch 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCOY, ANEB, CALC, and PASG Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$0.38 0.00 (0.00%) As of 07/2/2026 09:35 AM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.CalciMedica NASDAQ:CALC$0.97 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.94 -0.03 (-2.94%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Decoy Therapeutics NASDAQ:DCOY$7.31 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$6.94 -0.36 (-4.99%) As of 07/2/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Passage Bio NASDAQ:PASG$4.68 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.75 +0.07 (+1.50%) As of 07/2/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
